{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.168","value":"1.43"},{"groupId":"OG001","spread":"11.723","value":"-0.37"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"46"}],"units":"Participants"}],"title":"Change at Cycle 2"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.014","value":"1.75"},{"groupId":"OG001","spread":"10.740","value":"1.78"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"32"}],"units":"Participants"}],"title":"Change at Cycle 4"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.257","value":"4.23"},{"groupId":"OG001","spread":"13.108","value":"2.24"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"25"}],"units":"Participants"}],"title":"Change at Cycle 6"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.030","value":"5.96"},{"groupId":"OG001","spread":"10.809","value":"2.54"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"13"}],"units":"Participants"}],"title":"Change at Cycle 8"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.971","value":"6.61"},{"groupId":"OG001","spread":"15.040","value":"4.38"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"13"}],"units":"Participants"}],"title":"Change at Cycle 10"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.837","value":"7.94"},{"groupId":"OG001","spread":"21.024","value":"8.61"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"8"}],"units":"Participants"}],"title":"Change at Cycle 12"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.104","value":"9.04"},{"groupId":"OG001","spread":"13.615","value":"10.75"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"title":"Change at Cycle 14"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.230","value":"5.08"},{"groupId":"OG001","spread":"23.432","value":"7.88"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"4"}],"units":"Participants"}],"title":"Change at Cycle 16"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.067","value":"0.35"},{"groupId":"OG001","spread":"17.171","value":"-2.29"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"47"},{"groupId":"OG001","value":"37"}],"units":"Participants"}],"title":"Change at End of Treatment"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.385","value":"16.00"},{"groupId":"OG001","spread":"8.367","value":"-2.92"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"}],"units":"Participants"}],"title":"Change at 3-6 months LTFU"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.648","value":"-0.19"},{"groupId":"OG001","spread":"12.473","value":"-2.59"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"12"}],"units":"Participants"}],"title":"Change at 6-9 months LTFU"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.651","value":"3.62"},{"groupId":"OG001","spread":"10.555","value":"-5.32"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"10"}],"units":"Participants"}],"title":"Change at 9-12 months LTFU"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.918","value":"8.33"},{"groupId":"OG001","spread":"11.905","value":"-1.34"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"19"}],"units":"Participants"}],"title":"Change at 12-15 months LTFU"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.618","value":"3.03"},{"groupId":"OG001","spread":"14.756","value":"2.94"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"18"}],"units":"Participants"}],"title":"Change at 15-18 months LTFU"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.117","value":"3.35"},{"groupId":"OG001","spread":"14.316","value":"-0.19"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"16"}],"units":"Participants"}],"title":"Change at 18-21 months LTFU"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.471","value":"1.51"},{"groupId":"OG001","spread":"14.505","value":"0.61"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"18"}],"units":"Participants"}],"title":"Change at 21-24 months LTFU"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"7.952","value":"4.20"},{"groupId":"OG001","spread":"17.870","value":"1.42"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"15"}],"units":"Participants"}],"title":"Change at 24-27 months LTFU"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.488","value":"-1.57"},{"groupId":"OG001","spread":"8.716","value":"1.93"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"17"}],"units":"Participants"}],"title":"Change at 27-30 months LTFU"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.222","value":"-6.22"},{"groupId":"OG001","spread":"5.518","value":"-2.85"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"19"}],"units":"Participants"}],"title":"Change at >30 months LTFU"}],"denoms":[{"counts":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"64"}],"units":"Participants"}],"description":"FACT-G is a 27-item general cancer QOL instrument completed by participants receiving cancer treatment. FACT-G incorporates a 7-day recall period and contains 4 primary subscales: Physical Well-Being (PWB; sum of 7 items, point range 0-28); Social/Family Well-Being (SWB, sum of 7-items, point range 0-28); Emotional Well-Being (EWB; sum of 6-items, point range 0-24); Functional Well-Being (FWB; sum of 7-items, point range 0-28); Fact-G total score=sum of PWB, SWB, EWB, FWB, point range 0-108. Higher scores for the total scales and subscales indicate better quality of life. A negative change (reduction) from Baseline indicates improvement.","dispersionType":"Standard Deviation","groups":[{"description":"Brentuximab vedotin 1.8 mg/kg, intravenous over approximately 30 minutes, once on Day 1 of each 21-day cycle and may continue as monotherapy for up to a total of 16 cycles (48 weeks).","id":"OG000","title":"Brentuximab Vedotin"},{"description":"Methotrexate 5 to 50 mg, tablets, orally, once weekly (dose adjustment is guided by patient response and toxicity) or Bexarotene 300 mg/m\\^2, tablets, orally, once daily with meals for up to 48 weeks.","id":"OG001","title":"Methotrexate or Bexarotene"}],"paramType":"MEAN","populationDescription":"The ITT population included all participants who were identified as CD30+ by the Ventana anti-CD30 (Ber-H2) assay and were randomized to treatment. Here 'Number analyzed' is the number of participants with evaluable data at the specified time-point.","reportingStatus":"POSTED","timeFrame":"Day 1 of Cycles 1, 2, 4, 6, 8, 10, 12, 14, 16, at EOT and during posttreatment (LTFU) - (Median follow-up 38.8 months)","title":"Change From Baseline in Functional Assessment of Cancer Therapy General Questionnaire (FACT-G) Score","type":"SECONDARY","unitOfMeasure":"score on a scale"}